Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04607772
Title Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc

diffuse large B-cell lymphoma


Selinexor + Venetoclax

Ibrutinib + Rituximab + Selinexor

Lenalidomide + Rituximab + Selinexor

Lenalidomide + Selinexor + Tafasitamab-cxix

Bendamustine + Rituximab + Selinexor

Polatuzumab vedotin-piiq + Rituximab + Selinexor

Bendamustine + Polatuzumab vedotin-piiq + Rituximab + Selinexor

Gemcitabine + Oxaliplatin + Rituximab + Selinexor

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.